Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more
The precision cancer medicine ecosystem established in Norway and the ongoing implementation in the health care system are unique in an international context. The description of the entire ecosystem was published in Nature Medicine on May 5th. “These initiatives represent a triple-win effect,” says first author Kjetil Taskén, Head and Director of Institute of Cancer Research at Oslo University Hospital and Professor at University of Oslo. “The patients gain access to modern treatments; the researchers can investigate the effect of different medicines on new indications; and the industry can expand the application of their drugs.”
On the 21st of April, the 4x-great-grandchild of Frederik Holst - the first who defended a doctoral thesis in Norway, University of Christiania - Christian Holst Bergsland defended his thesis “Fluorescence-based multiplex immunohistochemistry in precision medicine of colorectal cancer” for the PhD degree at the Faculty of Medicine, University of Oslo. He received excellent assessment from the committee, both in the written report and during the defense. The first and second opponents were Professors Manuel Salto-Tellez, Institute for Cancer Research, London and Lars Akslen, University of Bergen. Professor Anne Hansen Ree was the chair of the evaluation committee.
In their largest single call ever, Norway's leading cancer researchers can now compete for a total of NOK 186 million from the Norwegian Cancer Society. While there previously were three annual announcements, everything is now gathered in the same call, called "Research Projects", meaning it is now sufficient for the researchers to submit one application. Then, international, independent peers assess the quality of the project and where it belongs topically.
Deadline for applications is May 31st.
NOK 130 million has been set aside for free research projects, NOK 28 million for breast cancer research and NOK 20 million for research on metastatic cancer. In addition, they are earmarking NOK 8 million for a high-quality project from an applicant community outside the three largest cities.
Hultcrantz M, Rustad EH, Yellapantula V, Jacob A, Akhlaghi T, Korde N, Mailankody S, Lesokhin AM, Hassoun H, Smith EL, Lahoud OB, Landau HJ, Shah GL, Scordo M, Chung DJ, Giralt S, Papaemmanuil E, Landgren O(2022) Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma Clin Cancer Res, 28(10), 2160-2166 DOI 10.1158/1078-0432.CCR-20-2995, PubMed 35553646